Novillus important dates and times
Dec. 2022Important Notices
Late December: The Partners Program Gaps in Care (CGMA) system will be updated. You will see membership through Dec. 15.
Dec. 31: You will be able to submit 2022 care gap and service event information to the CGMA until 11:59 p.m. EST.
Jan. 15: You will be able to submit reopened or rejected 2022 care gap and service event information to the CGMA until 11:59 p.m. EST. Service dates in 2023 will not be accepted at this time.
Jan. 16–March 5: The CGMA will be temporarily closed to prepare for the launch of the 2023 CGMA. You will not have access to the application during that time.
March 6: The 2023 CGMA—including 2023 care gaps and member rosters—will be available at 8 a.m. EST.
The delay in the system launch will allow claims received through January to be processed in February. The system will be updated to reflect 2023 gaps and new membership through Jan. 31, 2023.
Dec. 31: You will be able to submit 2022 care gap and service event information to the CGMA until 11:59 p.m. EST.
Jan. 15: You will be able to submit reopened or rejected 2022 care gap and service event information to the CGMA until 11:59 p.m. EST. Service dates in 2023 will not be accepted at this time.
Jan. 16–March 5: The CGMA will be temporarily closed to prepare for the launch of the 2023 CGMA. You will not have access to the application during that time.
March 6: The 2023 CGMA—including 2023 care gaps and member rosters—will be available at 8 a.m. EST.
The delay in the system launch will allow claims received through January to be processed in February. The system will be updated to reflect 2023 gaps and new membership through Jan. 31, 2023.
Recent Announcements
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates
HelpScript service helps patients enroll in manufacturer copay assistance programs
End-to-end provider support helps ensure a smooth submission processOct. 2025Important Notices